• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Atherosclerotic lower extremity peripheral artery disease (PAD) is increasingly recognized
as an important cause of cardiovascular morbidity and mortality that affects> 230 million …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …

Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Aims The expression of GADD153 (growth arrest and DNA damage-inducible gene 153), an
apoptosis-regulated gene, increases during endoplasmic reticulum (ER) stress. How …

Background. Atherothrombotic disease, including coronary artery disease (CAD) and
peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial …

Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …